Join UsContact Us|中EN
RareStone News
Breakthrough: Wakix® (Pitolisant) Becomes the First Insured Medication for Narcolepsy in China
[Shanghai, Dec 22, 2023] Today, RareStone Group announced the inclusion of Wakix (Pitolisant) in Chinas National Reimbursed Drug List (NRDL), marking a significant milestone in enhancing access to innovative medicines for narcolepsy in Chin...
MORE
date：2023-12-23
China NMPA approves RareStone’s pitolisant (Wakix) for the treatment of narcolepsy
pitolisant is the first and only treatment drug approved in mainland China for narcolepsy....
MORE
date：2023-07-05
The 1st Chinese narcolepsy patient study report released by CHARD and Peking University
The 1st Chinese narcolepsy patient study report released by CHARD and Peking University...
MORE
date：2022-10-31
RareStone won the Golden Snail Award 2022
RareStone won the Golden Snail Award 2022 RareStone announced that RareStone and Biogen are named the winner of the Golden Snail Award 2022. Sponsored by the Chinese Organization for Rare Disorders, the prestigious Golden Snail Award is the...
MORE
date：2022-09-02
the China Alliance for Rare Diseases (CHARD) and the Chinese Red Cross Foundation (CRCF) jointly initiated the ＂Rare Disease Mutual Assistance Fund＂
- RareStone Group provided the first batch of donations to the foundation . December 18th, during the 2021 China Conference on Rare Diseases in Beijing, the China Alliance for Rare Diseases (CHARD) and the Chinese Red Cross Foundation (CRCF...
MORE
date：2021-12-24
RareStone Group & Rhythm Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotid
-- RareStone to seek marketing authorization for IMCIVREE to treat obesity due to biallelic POMC, PCSK1 and LEPR deficiencies and Bardet-Biedl and Alstrm syndromes in mainland China, Hong Kong and Macau BOSTON,December 2, 2021--RareStone Gro...
MORE
date：2021-12-24
RareStone Inc. Announces Strategic Collaboration with Tencent on a Service Ecosystem Focused on Rare Disease Patients in China
BOSTON, Mass., July 27, 2021 RareStone Inc., formerly Citrine Medicine, aChina-based rare disease company, and Tencent Holdings Limited (Tencent), based in Shenzhen, China, signed a strategic collaboration memorandum to develop a service eco...
MORE
date：2021-07-27
Citrine Medicine Announces Approval of Wakix®(pitolisant) for Named Patient Program in China
The narcolepsy drug Wakix can now be prescribed to patients in China with urgent unmet medical needs BOSTON, Mass., and Boao, Hainan, China, May 07, 2021 Citrine Medicine, aChina-based rare disease therapeutics company, today announced that...
MORE
date：2021-05-07
Citrine Medicine And Sinopharm Group Announce Strategic Partnership To Broaden And Accelerate Access To Rare Disease Drugs In China
Collaboration to focus on establishing supply chain and securing distribution channels for delivering rare disease therapies to patients across China BOSTON, Mass., and SHANGHAI, China, April 19, 2021 Citrine Medicine, aChina-based rare dis...
MORE
date：2021-03-29
Citrine Medicine Announces Strategic Partnership To Bring Alkindi® To China For Use In Pediatric Congenital Adrenal Hyperplasia (CAH)
CAMBRIDGE, Mass. and SHANGHAI , Jan. 27, 2021 -- Citrine Medicine , aChina-based rare disease therapeutics company,today announced that it has entered into a licensing agreement with Diurnal Group plc (AIM: DNL), a specialty pharmaceutical...
MORE
date：2021-03-21
Industry News